TriSalus Life Sciences (NASDAQ:TLSI) Price Target Raised to $12.00

TriSalus Life Sciences (NASDAQ:TLSI) had its target price lifted by HC Wainwright from $11.00 to $12.00 in a report issued on Wednesday morning, MarketBeat reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for TriSalus Life Sciences’ Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at ($0.04) EPS and FY2026 earnings at ($0.53) EPS.

TLSI has been the subject of several other research reports. Wall Street Zen upgraded shares of TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research note on Sunday, August 23rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TriSalus Life Sciences in a report on Friday, August 7th. Finally, Zacks Research upgraded shares of TriSalus Life Sciences to a “hold” rating in a research note on Thursday, September 10th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $10.20.

TriSalus Life Sciences Trading Down 5.9%

Shares of TLSI opened at $4.34 on Wednesday. The business has a 50-day moving average of $4.90 and a 200 day moving average of $4.32. TriSalus Life Sciences has a fifty-two week low of $2.20 and a fifty-two week high of $7.95. The firm has a market cap of $267.26 million, a P/E ratio of -3.34 and a beta of 0.44. The company has a debt-to-equity ratio of 5.05, a quick ratio of 4.97 and a current ratio of 5.35.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.16). The firm had revenue of $11.41 million during the quarter, compared to the consensus estimate of $10.27 million. As a group, research analysts forecast that TriSalus Life Sciences will post -0.53 EPS for the current year.

Institutional Investors Weigh In On TriSalus Life Sciences

Several large investors have recently added to or reduced their stakes in TLSI. First Light Asset Management LLC purchased a new stake in shares of TriSalus Life Sciences in the 1st quarter valued at about $20,267,000. BlackRock Inc. purchased a new position in shares of TriSalus Life Sciences during the second quarter worth about $12,099,000. Nantahala Capital Management LLC purchased a new position in shares of TriSalus Life Sciences during the second quarter worth about $4,550,000. Perkins Capital Management Inc. bought a new position in shares of TriSalus Life Sciences in the first quarter worth approximately $920,000. Finally, Wasatch Advisors LP bought a new position in shares of TriSalus Life Sciences in the first quarter worth approximately $5,752,000. Institutional investors own 2.58% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences is an oncology company focused on developing technologies and therapies for patients with liver and pancreatic tumors. The company’s approach combines investigational immunotherapies with drug-delivery technologies intended to improve treatment access to solid tumors, which can be difficult to reach through conventional systemic administration.

TriSalus is best known for its Pressure-Enabled Drug Delivery (PEDD) platform, which is designed to deliver medicines directly into tumors or their surrounding blood vessels by using controlled pressure.